Anifrolumab Biosimilar – Anti-IFNAR1 mAb – Research Grade

Reference:
Size

,

Isotype

IgG1, kappa

Brand

Product type

Clonality

Expression system

Applications

,

Product nameAnifrolumab Biosimilar - Anti-IFNAR1 mAb - Research Grade
SourceCAS 1326232-46-5
SpeciesHomo sapiens
Purity>85%
BufferPBS buffer PH7.5
Delivery conditionBlue ice (+4°C)
Delivery Time3-5 days if in stock; 3-5 weeks if production needed
Storage conditionstore at -80°C
BrandProteoGenix
Aliases /SynonymsAnifrolumab,MDX-1333,MEDI-546,IFNAR1,anti-IFNAR1
ReferencePX-TA1332
NoteFor research use only. Not suitable for clinical or therapeutic use.
IsotypeIgG1-kappa
ClonalityMonoclonal Antibody

Description of Anifrolumab Biosimilar - Anti-IFNAR1 mAb - Research Grade

General information on Anti-IFNAR1[Homo sapiens] (Anifrolumab) Monoclonal Antibody

Anifrolumab has been studied to treat Scleroderma. Anifrolumab, or MEDI546, is a human monoclonal antibody of IgG1 type. It is able to bind to interferon (IFN) alpha receptors 1 (IFNAR1). This bond blocks type I IFN signaling. Anifrolumab is carrying three mutations (L234F/L235E/P331S) in the heavy chain. Those mutations aim to reduce the cell surface Fc gamma receptor and potential Fc mediated effector function. Indeed, antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) are mechanisms depending on these parts. Anifrolumab is developed to treat systemic lupus erythematosus (SLE) and lupus nephritis.

About Systemic Lupus Erythematosus (SLE)

SLE is an autoimmune disease which is characterized by its chronicity and mustisystem affections. SLE is evolving by succession of inflammatory phases and remissions. Many evidences are showing the role of type I IFNs in the pathogenesis of this immunologic disease. Increased type I IFN expression and type I IFN-induced cell signalling correlate with SLE severity. Numerous genetic polymorphisms increase susceptibility to SLE by increasing type I IFN signaling.

About interferons

Type I IFNs family includes IFN-α subtypes, IFN-β, IFN-δ, IFN-ε, IFN-κ and IFN-ω. These interferons and their receptors, the IFN alpha receptors 1 (IFNAR1) and 2 (IFNAR2), form a IFNAR complex with specific functions. This complex is leading to tyrosine phosphorylation of signal transducer and activator of transcription 1 (STAT1) and 2 (STAT2). Once phosphorylated, STAT1 and STAT2 translocate with IFN regulatory factor 9 (IRF9) to the nucleus. Then, they drive IFN-stimulated response element (ISRE) activation. ISRE promotes transcription of multiple IFN-stimulated genes: which leads to the production of proinflammatory and immunomodulatory proteins involved in the host innate immune response to viral infection.

SDS-PAGE for Anifrolumab Biosimilar - Anti-IFNAR1 mAb

Anifrolumab Biosimilar - Anti-IFNAR1 mAb, on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.

Publication

  • Samantha Bannister, Bowon Kim, Jorge Domínguez-Andrés, Gizem Kilic , Brendan R. E. Ansell , Melanie R. Neeland , Simone J. C. F. M. Moorlag et al. Neonatal BCG vaccination is associated with a long-term DNA methylation signature in circulating monocytes, 5 aug 2022, Science Advances, Vol8, Issue31 [https://www.science.org/doi/full/10.1126/sciadv.abn4002]

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “Anifrolumab Biosimilar – Anti-IFNAR1 mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Related products

IFNAR1, C-His, recombinant protein
Antigen

IFNAR1, C-His, recombinant protein

PX-P5766 500$
Human IgG1 LALA Isotype Control antibody (HyHEL-10)
Isotype Control

Human IgG1 LALA Isotype Control antibody (HyHEL-10)

PTX17885 214$
Anifrolumab ELISA Kit
ELISA

Anifrolumab ELISA Kit

KPTX200 1547$

Contact us

Send us a message from the form below







    Cart (0 Items)

    Your cart is currently empty.

    View Products